Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Infinity Pharmaceuticals management to meet virtually with Oppenheimer » 04:55
11/05/21
11/05
04:55
11/05/21
04:55
INFI

Infinity Pharmaceuticals

$2.64 /

-0.065 (-2.40%)

Virtual Meeting to be…

Virtual Meeting to be held on November 5 hosted by Oppenheimer.

ShowHide Related Items >><<
INFI Infinity Pharmaceuticals
$2.64 /

-0.065 (-2.40%)

INFI Infinity Pharmaceuticals
$2.64 /

-0.065 (-2.40%)

10/18/21 H.C. Wainwright
Infinity Pharmaceuticals initiated with a Buy at H.C. Wainwright
08/02/21 JPMorgan
JPMorgan upgrades Infinity Pharmaceuticals on urothelial cancer opportunity
08/02/21 JPMorgan
Infinity Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
07/28/21 B. Riley
Infinity Pharmaceuticals price target lowered to $4 from $7 at B. Riley
INFI Infinity Pharmaceuticals
$2.64 /

-0.065 (-2.40%)

  • 12
    Feb
INFI Infinity Pharmaceuticals
$2.64 /

-0.065 (-2.40%)

INFI Infinity Pharmaceuticals
$2.64 /

-0.065 (-2.40%)

Hot Stocks
Infinity Pharmaceuticals sees FY21 net loss ($50M)-($40M) » 16:20
11/02/21
11/02
16:20
11/02/21
16:20
INFI

Infinity Pharmaceuticals

$2.64 /

+0.005 (+0.19%)

Infinity expects to end…

Infinity expects to end 2021 with a year-end-cash, cash equivalents and available for sale securities balance ranging from $70M-$80M. Infinity's financial guidance does not include additional funding or business development activities.

ShowHide Related Items >><<
INFI Infinity Pharmaceuticals
$2.64 /

+0.005 (+0.19%)

INFI Infinity Pharmaceuticals
$2.64 /

+0.005 (+0.19%)

10/18/21 H.C. Wainwright
Infinity Pharmaceuticals initiated with a Buy at H.C. Wainwright
08/02/21 JPMorgan
JPMorgan upgrades Infinity Pharmaceuticals on urothelial cancer opportunity
08/02/21 JPMorgan
Infinity Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
07/28/21 B. Riley
Infinity Pharmaceuticals price target lowered to $4 from $7 at B. Riley
INFI Infinity Pharmaceuticals
$2.64 /

+0.005 (+0.19%)

  • 12
    Feb
INFI Infinity Pharmaceuticals
$2.64 /

+0.005 (+0.19%)

INFI Infinity Pharmaceuticals
$2.64 /

+0.005 (+0.19%)

Earnings
Infinity Pharmaceuticals reports Q3 EPS (12c), consensus (13c) » 16:19
11/02/21
11/02
16:19
11/02/21
16:19
INFI

Infinity Pharmaceuticals

$2.64 /

+0.005 (+0.19%)

"Infinity had a very…

"Infinity had a very successful 3rd quarter reaching major clinical milestones with eganelisib and welcoming two outstanding R&D executives to our management team," said Adelene Perkins, CEO and Chair, Infinity Pharmaceuticals. "In particular, data presented in July from MARIO-3 and MARIO-275 show that eganelisib, with its unique role in reprogramming macrophages, increases the effectiveness of current checkpoint inhibitors and improves patient outcomes across multiple indications and treatment settings. These data show that eganelisib has the potential to drive the next generation of cancer immuno-therapy." At September 30, 2021, Infinity had total cash, cash equivalents and available-for-sale securities of $90.1 million, compared to $97.3 million at June 30, 2021.

ShowHide Related Items >><<
INFI Infinity Pharmaceuticals
$2.64 /

+0.005 (+0.19%)

INFI Infinity Pharmaceuticals
$2.64 /

+0.005 (+0.19%)

10/18/21 H.C. Wainwright
Infinity Pharmaceuticals initiated with a Buy at H.C. Wainwright
08/02/21 JPMorgan
JPMorgan upgrades Infinity Pharmaceuticals on urothelial cancer opportunity
08/02/21 JPMorgan
Infinity Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
07/28/21 B. Riley
Infinity Pharmaceuticals price target lowered to $4 from $7 at B. Riley
INFI Infinity Pharmaceuticals
$2.64 /

+0.005 (+0.19%)

  • 12
    Feb
INFI Infinity Pharmaceuticals
$2.64 /

+0.005 (+0.19%)

INFI Infinity Pharmaceuticals
$2.64 /

+0.005 (+0.19%)

Options
Infinity Pharmaceuticals options imply 10.6% move in share price post-earnings » 14:34
11/02/21
11/02
14:34
11/02/21
14:34
INFI

Infinity Pharmaceuticals

$2.57 /

-0.065 (-2.47%)

Pre-earnings options…

Pre-earnings options volume in Infinity Pharmaceuticals is 2.3x normal with calls leading puts 14:1. Implied volatility suggests the market is anticipating a move near 10.6%, or 27c, after results are released. Median move over the past eight quarters is 3.4%.

ShowHide Related Items >><<
INFI Infinity Pharmaceuticals
$2.57 /

-0.065 (-2.47%)

INFI Infinity Pharmaceuticals
$2.57 /

-0.065 (-2.47%)

10/18/21 H.C. Wainwright
Infinity Pharmaceuticals initiated with a Buy at H.C. Wainwright
08/02/21 JPMorgan
JPMorgan upgrades Infinity Pharmaceuticals on urothelial cancer opportunity
08/02/21 JPMorgan
Infinity Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
07/28/21 B. Riley
Infinity Pharmaceuticals price target lowered to $4 from $7 at B. Riley
INFI Infinity Pharmaceuticals
$2.57 /

-0.065 (-2.47%)

  • 12
    Feb
INFI Infinity Pharmaceuticals
$2.57 /

-0.065 (-2.47%)

Conference/Events
Infinity Pharmaceuticals management to meet virtually with Oppenheimer » 15:35
11/01/21
11/01
15:35
11/01/21
15:35
INFI

Infinity Pharmaceuticals

$2.64 /

+0.1 (+3.94%)

Virtual Meeting to be…

Virtual Meeting to be held on November 5 hosted by Oppenheimer.

ShowHide Related Items >><<
INFI Infinity Pharmaceuticals
$2.64 /

+0.1 (+3.94%)

INFI Infinity Pharmaceuticals
$2.64 /

+0.1 (+3.94%)

10/18/21 H.C. Wainwright
Infinity Pharmaceuticals initiated with a Buy at H.C. Wainwright
08/02/21 JPMorgan
JPMorgan upgrades Infinity Pharmaceuticals on urothelial cancer opportunity
08/02/21 JPMorgan
Infinity Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
07/28/21 B. Riley
Infinity Pharmaceuticals price target lowered to $4 from $7 at B. Riley
INFI Infinity Pharmaceuticals
$2.64 /

+0.1 (+3.94%)

  • 12
    Feb
INFI Infinity Pharmaceuticals
$2.64 /

+0.1 (+3.94%)

Conference/Events
Infinity Pharmaceuticals management to meet virtually with Truist » 04:55
11/01/21
11/01
04:55
11/01/21
04:55
INFI

Infinity Pharmaceuticals

$2.54 /

-0.03 (-1.17%)

Virtual Meeting to be…

Virtual Meeting to be held on November 1 hosted by Truist.

ShowHide Related Items >><<
INFI Infinity Pharmaceuticals
$2.54 /

-0.03 (-1.17%)

INFI Infinity Pharmaceuticals
$2.54 /

-0.03 (-1.17%)

10/18/21 H.C. Wainwright
Infinity Pharmaceuticals initiated with a Buy at H.C. Wainwright
08/02/21 JPMorgan
JPMorgan upgrades Infinity Pharmaceuticals on urothelial cancer opportunity
08/02/21 JPMorgan
Infinity Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
07/28/21 B. Riley
Infinity Pharmaceuticals price target lowered to $4 from $7 at B. Riley
INFI Infinity Pharmaceuticals
$2.54 /

-0.03 (-1.17%)

  • 12
    Feb
INFI Infinity Pharmaceuticals
$2.54 /

-0.03 (-1.17%)

Over a month ago
Conference/Events
Infinity Pharmaceuticals management to meet virtually with Piper Sandler » 04:55
10/26/21
10/26
04:55
10/26/21
04:55
INFI

Infinity Pharmaceuticals

$2.52 /

-0.07 (-2.70%)

Virtual Meeting to be…

Virtual Meeting to be held on October 26 hosted by Piper Sandler.

ShowHide Related Items >><<
INFI Infinity Pharmaceuticals
$2.52 /

-0.07 (-2.70%)

INFI Infinity Pharmaceuticals
$2.52 /

-0.07 (-2.70%)

10/18/21 H.C. Wainwright
Infinity Pharmaceuticals initiated with a Buy at H.C. Wainwright
08/02/21 JPMorgan
JPMorgan upgrades Infinity Pharmaceuticals on urothelial cancer opportunity
08/02/21 JPMorgan
Infinity Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
07/28/21 B. Riley
Infinity Pharmaceuticals price target lowered to $4 from $7 at B. Riley
INFI Infinity Pharmaceuticals
$2.52 /

-0.07 (-2.70%)

  • 12
    Feb
INFI Infinity Pharmaceuticals
$2.52 /

-0.07 (-2.70%)

Conference/Events
Infinity Pharmaceuticals management to meet virtually with Truist » 10:58
10/25/21
10/25
10:58
10/25/21
10:58
INFI

Infinity Pharmaceuticals

$2.55 /

-0.04 (-1.54%)

Virtual Meeting to be…

Virtual Meeting to be held on November 1 hosted by Truist.

ShowHide Related Items >><<
INFI Infinity Pharmaceuticals
$2.55 /

-0.04 (-1.54%)

INFI Infinity Pharmaceuticals
$2.55 /

-0.04 (-1.54%)

10/18/21 H.C. Wainwright
Infinity Pharmaceuticals initiated with a Buy at H.C. Wainwright
08/02/21 JPMorgan
JPMorgan upgrades Infinity Pharmaceuticals on urothelial cancer opportunity
08/02/21 JPMorgan
Infinity Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
07/28/21 B. Riley
Infinity Pharmaceuticals price target lowered to $4 from $7 at B. Riley
INFI Infinity Pharmaceuticals
$2.55 /

-0.04 (-1.54%)

  • 12
    Feb
INFI Infinity Pharmaceuticals
$2.55 /

-0.04 (-1.54%)

Conference/Events
Infinity Pharmaceuticals management to meet virtually with Piper Sandler » 10:34
10/21/21
10/21
10:34
10/21/21
10:34
INFI

Infinity Pharmaceuticals

$2.70 /

+0.04 (+1.50%)

Virtual Meeting to be…

Virtual Meeting to be held on October 26 hosted by Piper Sandler.

ShowHide Related Items >><<
INFI Infinity Pharmaceuticals
$2.70 /

+0.04 (+1.50%)

INFI Infinity Pharmaceuticals
$2.70 /

+0.04 (+1.50%)

10/18/21 H.C. Wainwright
Infinity Pharmaceuticals initiated with a Buy at H.C. Wainwright
08/02/21 JPMorgan
JPMorgan upgrades Infinity Pharmaceuticals on urothelial cancer opportunity
08/02/21 JPMorgan
Infinity Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
07/28/21 B. Riley
Infinity Pharmaceuticals price target lowered to $4 from $7 at B. Riley
INFI Infinity Pharmaceuticals
$2.70 /

+0.04 (+1.50%)

  • 12
    Feb
INFI Infinity Pharmaceuticals
$2.70 /

+0.04 (+1.50%)

Initiation
Infinity Pharmaceuticals initiated with a Buy at H.C. Wainwright » 06:16
10/18/21
10/18
06:16
10/18/21
06:16
INFI

Infinity Pharmaceuticals

$2.65 /

-0.045 (-1.67%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Michael King initiated coverage of Infinity Pharmaceuticals with a Buy rating and $9 price target. The analyst believes the results presented in 2021 would be sufficient to support regulatory approval of eganelisib and a successful commercial opportunity.

ShowHide Related Items >><<
INFI Infinity Pharmaceuticals
$2.65 /

-0.045 (-1.67%)

INFI Infinity Pharmaceuticals
$2.65 /

-0.045 (-1.67%)

08/02/21 JPMorgan
JPMorgan upgrades Infinity Pharmaceuticals on urothelial cancer opportunity
08/02/21 JPMorgan
Infinity Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
07/28/21 B. Riley
Infinity Pharmaceuticals price target lowered to $4 from $7 at B. Riley
07/28/21 Wells Fargo
Infinity Pharmaceuticals upgraded to Overweight at Wells Fargo
INFI Infinity Pharmaceuticals
$2.65 /

-0.045 (-1.67%)

  • 12
    Feb
INFI Infinity Pharmaceuticals
$2.65 /

-0.045 (-1.67%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.